Phase 2 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part A (Healthy Volunteer Phase):
- People who are male, or female and not able to become pregnant, and are in general good health
Part B (Patient Phase):
- People who have a confirmed diagnosis of pulmonary arterial hypertension (a type of high blood pressure affecting the lungs)
- People whose lung blood vessel resistance has been measured at a specific level (≥400 dyn.sec.cm-5) before the study begins (confirm with trial site)
- People who are already receiving stable, ongoing standard treatments for their condition
- People who are able to walk between 150 and 450 metres in a 6-minute walk test
Who may not be able to join:
Part A (Healthy Volunteer Phase):
- People who have significant heart rhythm problems or other heart abnormalities
- People who have had surgery or have a medical condition that could affect how the body processes medication, or that could put them at risk during the study
- For Japanese-specific groups: people who are not first to third generation Japanese, as defined in the study protocol (confirm with trial site)
Part B (Patient Phase):
- People who have a surgical or medical condition that could put them at greater risk by participating in the study
- Women who are able to become pregnant, unless highly effective contraception is being used
- Males who are sexually active and unwilling to use a condom during and for 24 hours after stopping study treatment
- People who have had an allergic reaction to any of the study treatments or their ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs); Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR); Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.